Loading

[ 2012/06/29 | Astellas Pharma Inc. | Pharmaceuticals | Tokyo | TSE1, OSE1 ]

FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas (pdf 121KB)


The Company's Official Page
http://www.astellas.com/en/corporate/news/detail/fda-approves-overactive-bladde.html
Back To Previous Page

FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas (pdf 121KB)

June 29, 2012

Printer-friendly version

FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas (pdf 121KB)


Related Latest News
"Astellas Pharma Inc." more
"Pharmaceuticals" Listed Companies more
"Tokyo" Companies more
WARNING: (1) Because this website uses a computer program to automatically collect and display press-release text information, errors or inaccuracy may occur. Double-check with information on these companies' official websites. (2) A press release may contain facts, figures and preliminary forward-looking statements which are subject to change.
Press Conferense Videos
Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays
Sharp Corporation 2012/06/01
More Videos
Latest Press Release Search

Save favorite searches Hot keywords

Fukushima | power supply | cloud | solar
*NOTE: Recommended keywords shown above.
Your Most Recently Viewed Companies
Visit any of the company pages in JPubb, and your most recently viewed companies will automatically show up here.

Erase all This feature:ON How to use
Most Popular: Astellas Pharma Inc.
1. Announcement of Approval of Additional Indications for the Selective COX-2 Inhibitor Celecox® Tablets in Japan
2009/06/17
2. Astellas and UCB announce approval of Cimzia®(certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis
2012/12/25
3. AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
2013/05/07
4. MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS (pdf 96KB)
2012/10/22
Feed
Releases by Prefecture
Hokkaido | Aomori | Iwate | Miyagi | Akita | Yamagata | Fukushima

Ibaraki | Tochigi | Gunma | Saitama | Chiba | Tokyo | Kanagawa

Niigata | Toyama | Ishikawa | Fukui | Yamanashi | Nagano

Gifu | Shizuoka | Aichi | Mie

Shiga | Kyoto | Osaka | Hyogo | Nara | Wakayama

Tottori | Shimane | Okayama | Hiroshima | Yamaguchi

Tokushima | Kagawa | Ehime | Kochi

Fukuoka | Saga | Nagasaki | Kumamoto | Oita | Miyazaki | Kagoshima | Okinawa
Releases by Stock Exchange
TSE (Tokyo) All | TSE1 | TSE2 | Mothers

OSE (Osaka) All | OSE1 | OSE2 | JASDAQ Standard | JASDAQ Growth

NSE (Nagoya) All | NSE1 | NSE2 | Centrex | NSE-only

SSE (Sapporo) All | Ambitious | SSE-only

FSE (Fukuoka) All | Q-Board | FSE-only
Press Release Search
Company
Industry
Prefecture
Stock Exchange
Date
(yyyy/mm/dd)		 //～
//
Listed or Non-listed
*NOTE: Please input only items to be specified.
*NOTE: The "date" here means the one on which a press release is uploaded on this website. So it isn't necessarily the same as its official announcement date.
Company Search
Company
Industry
Prefecture
Stock Exchange
Listed or Non-listed
*NOTE: Please input only items to be specified.